{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:28:24Z","timestamp":1761676104653},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.cpet.2013.08.006","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T21:03:18Z","timestamp":1380661398000},"page":"459-467","source":"Crossref","is-referenced-by-count":5,"title":["Dopamine Transporter SPECT Imaging in Parkinson Disease and Dementia"],"prefix":"10.1016","volume":"8","author":[{"given":"Devaki Shilpa","family":"Surasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Peller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rathan M.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for Parkinson disease","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2013.08.006_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0733-8619(05)70259-0","article-title":"Epidemiology of Parkinson's disease","volume":"14","author":"Tanner","year":"1996","journal-title":"Neurol Clin"},{"issue":"6","key":"10.1016\/j.cpet.2013.08.006_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/jnnp.57.6.672","article-title":"Parkinson's disease","volume":"57","author":"Marsden","year":"1994","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"8","key":"10.1016\/j.cpet.2013.08.006_bib4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/jnnp.2004.060186","article-title":"Neurodegenerative disorders: Parkinson's disease and Huntington's disease","volume":"76","author":"Hague","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"11","key":"10.1016\/j.cpet.2013.08.006_bib5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/jm00037a004","article-title":"N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters","volume":"37","author":"Neumeyer","year":"1994","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.cpet.2013.08.006_bib6","first-page":"162","article-title":"Pharmaceutical Approval Update","volume":"36","author":"Marvin","year":"2011"},{"issue":"3 Pt 1","key":"10.1016\/j.cpet.2013.08.006_bib7","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1523\/JNEUROSCI.15-03-01714.1995","article-title":"The dopamine transporter: immunochemical characterization and localization in brain","volume":"15","author":"Ciliax","year":"1995","journal-title":"J\u00a0Neurosci"},{"issue":"14","key":"10.1016\/j.cpet.2013.08.006_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","article-title":"Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications","volume":"318","author":"Kish","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cpet.2013.08.006_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-008-0729-x","article-title":"Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT","volume":"35","author":"Varrone","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2013.08.006_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","article-title":"EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2","volume":"37","author":"Darcourt","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2013.08.006_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00259-007-0621-0","article-title":"Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs","volume":"35","author":"Booij","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.cpet.2013.08.006_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00006231-200512000-00015","article-title":"Comparison of different methods of DatSCAN quantification","volume":"26","author":"Morton","year":"2005","journal-title":"Nucl Med Commun"},{"issue":"Pt 5","key":"10.1016\/j.cpet.2013.08.006_bib13","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1212\/WNL.46.1.231","article-title":"[123I] beta-CIT\/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease","volume":"46","author":"Marek","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.cpet.2013.08.006_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2377-7-27","article-title":"Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes","volume":"7","author":"Vlaar","year":"2007","journal-title":"BMC Neurol"},{"issue":"10\u201312","key":"10.1016\/j.cpet.2013.08.006_bib16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s007020050124","article-title":"[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease","volume":"105","author":"Asenbaum","year":"1998","journal-title":"J\u00a0Neural Transm"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R","article-title":"[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients","volume":"16","author":"Haapaniemi","year":"2001","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.cpet.2013.08.006_bib18","first-page":"1303","article-title":"Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging","volume":"42","author":"Huang","year":"2001","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000007896","article-title":"[123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients","volume":"39","author":"Muller","year":"1998","journal-title":"Eur Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2013.08.006_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.57.2.205","article-title":"Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis","volume":"57","author":"Schwarz","year":"2000","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.cpet.2013.08.006_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-004-1480-6","article-title":"Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1","volume":"31","author":"Van Laere","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.cpet.2013.08.006_bib22","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A\u00a0controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","author":"Parkinson Study Group","year":"2002","journal-title":"Arch Neurol"},{"issue":"24","key":"10.1016\/j.cpet.2013.08.006_bib23","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"Pt 2","key":"10.1016\/j.cpet.2013.08.006_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/brain\/119.2.585","article-title":"An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease","volume":"119","author":"Morrish","year":"1996","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.1265","article-title":"Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study","volume":"17","author":"Pirker","year":"2002","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.cpet.2013.08.006_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00006231-200106000-00017","article-title":"Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years","volume":"22","author":"Chouker","year":"2001","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1016\/j.cpet.2013.08.006_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s007020070077","article-title":"Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT","volume":"107","author":"Staffen","year":"2000","journal-title":"J\u00a0Neural Transm"},{"issue":"3","key":"10.1016\/j.cpet.2013.08.006_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J","article-title":"Effect of treatment with l-dopa\/carbidopa or l-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT","volume":"14","author":"Innis","year":"1999","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.cpet.2013.08.006_bib29","first-page":"629","article-title":"2010. Prog Neurobiol","volume":"95","author":"The Parkinson's Progression Markers Initiative (PPMI)","year":"2011"},{"issue":"Suppl 12","key":"10.1016\/j.cpet.2013.08.006_bib30","first-page":"S315","article-title":"Advanced strategies for treatment of Parkinson's disease: the role of early treatment","volume":"17","author":"Jann","year":"2011","journal-title":"Am J Manag Care"},{"issue":"13","key":"10.1016\/j.cpet.2013.08.006_bib31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression","volume":"287","author":"Parkinson Study Group","year":"2002","journal-title":"JAMA"},{"issue":"Suppl 4","key":"10.1016\/j.cpet.2013.08.006_bib32","first-page":"IV37","article-title":"Does levodopa slow or hasten the rate of progression of Parkinson's disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shin","year":"2012","journal-title":"J\u00a0Clin Neurol"},{"issue":"6","key":"10.1016\/j.cpet.2013.08.006_bib34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","article-title":"Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa","volume":"51","author":"Hardie","year":"1988","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.cpet.2013.08.006_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","article-title":"[123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease","volume":"21","author":"Lorberboym","year":"2006","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.cpet.2013.08.006_bib36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","article-title":"The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism","volume":"28","author":"Booij","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2013.08.006_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12149-012-0577-4","article-title":"SPECT study with I-123-ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?","volume":"26","author":"Gerasimou","year":"2012","journal-title":"Ann Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2013.08.006_bib38","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/mds.21157","article-title":"Report from a U.S. conference on essential tremor","volume":"21","author":"Elble","year":"2006","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.410340115","article-title":"A\u00a0positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections","volume":"34","author":"Jenkins","year":"1993","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.cpet.2013.08.006_bib40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MNM.0b013e3282f4d307","article-title":"Striatal dopamine transporter abnormalities in patients with essential tremor","volume":"29","author":"Isaias","year":"2008","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.cpet.2013.08.006_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","article-title":"Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2013.08.006_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archneur.59.1.43","article-title":"Research evaluation and prospective diagnosis of dementia with Lewy bodies","volume":"59","author":"Lopez","year":"2002","journal-title":"Arch Neurol"},{"issue":"Pt 8","key":"10.1016\/j.cpet.2013.08.006_bib44","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/brain\/122.8.1449","article-title":"Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution","volume":"122","author":"Piggott","year":"1999","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.cpet.2013.08.006_bib45","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.cpet.2013.08.006_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859813000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859813000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T03:15:03Z","timestamp":1564283703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859813000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1556859813000680"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2013.08.006","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}